{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":1,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":19,"n_cols":5,"rows_kept":19,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[6,2,6,3],[7,2,7,3],[9,2,9,3],[10,2,10,3],[14,2,14,3],[15,2,15,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910136278803321"]
[null,null,"Autore",null,"Robert Marr"]
[null,null,"Titolo",null,"Amyloid-beta clearance in Alzheimer's disease [[electronic resource] /] / topic editors: Robert A. Marr and Eliezer Masliah"]
[null,null,"Pubbl/distr/stampa",null,"Frontiers Media SA, 2015"]
[{"$nulls":4},"[Place of publication not identified] : , : Frontiers Media SA, , 2015"]
[{"$nulls":4},"©2015"]
[null,null,"Descrizione fisica",null,"1 online resource (111 pages) : illustrations; digital, PDF file(s)"]
[null,null,"Collana",null,"Frontiers research topics"]
[{"$nulls":4},"Frontiers in aging neuroscience"]
[null,null,"Disciplina",null,"616.831"]
[null,null,"Soggetti",null,"Alzheimer's disease"]
[{"$nulls":4},"Alzheimer's disease - Pathogenesis"]
[{"$nulls":4},"Alzheimer's disease - Molecular aspects"]
[{"$nulls":4},"Neurosciences"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,null,"Sommario/riassunto","Strong evidence continues to accumulate indicating that amyloid-beta (Aβ) is a central part of Alzheimer’s disease (AD) pathogenesis in spite of the negative evidence coming from failed clinical trials. Therefore, mechanisms of clearance of Aβ are of great interest in understanding AD pathogenesis and the development of effective treatments. This topic focuses on the issues related to Aβ clearance in AD. The topics covered include proteases that degrade Aβ and their localization, regulation, and functions. This topic also covers issues related to clearance through uptake by glia and through low-density lipoprotein (LDL) receptor mediated mechanisms. Signal transduction related to AD pathology and clearance is also addressed. Finally, immunotherapy and other novel therapeutic approaches are discussed."]